MLL (KMT2A) Gene Rearrangement by FISH – AML/ALL Panel in UAE | 700 AED

Executive Summary & Core Metrics

Executive Summary – Clinical Trust & Transparency

Your MLL (KMT2A) gene rearrangement analysis is processed in our ISO 9001:2015–certified molecular diagnostics facility (DHA License No. 1143, Dubai Healthcare City). The assay delivers 99.9% diagnostic sensitivity via targeted dual-color break-apart FISH probes on bone marrow aspirate or peripheral blood specimens. Results are available within 3–4 working days and include a complimentary post-test telephonic clinical guidance session with our oncology support team. The test price is 700 AED, with insurance pre-authorization support available via WhatsApp at +971 54 548 8731 (share your Emirates ID and policy number for real-time eligibility checks).

Important: Sample collection for this test is a hospital-only procedure. Bone marrow aspiration or peripheral blood draw must be performed at an accredited healthcare facility. Mobile home phlebotomy is not available for this test.

Test Overview & Methodology

The MLL (Mixed Lineage Leukemia, now designated KMT2A) gene rearrangement test is a high-resolution fluorescence in-situ hybridization (FISH) assay that detects clinically significant translocations involving chromosome band 11q23 in bone marrow or peripheral blood. This test is essential for risk stratification in both acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), guiding targeted therapy decisions and allogeneic stem cell transplant timing. Under DHA and MOHAP precision medicine frameworks, a validated prescription from your attending oncologist is mandatory before testing.

Feature	Our Gold-Standard FISH (MLL/KMT2A)	Closest Alternative (RT-PCR or Conventional Karyotype)
Diagnostic Precision	Probe-level resolution of break-apart signals; detects all fusion partners; 99.9% sensitivity	May miss atypical fusions or require viable metaphase cells; lower sensitivity in cryptic rearrangements
Turnaround Time	3–4 working days (interphase nuclei; no culture required)	5–10 days (karyotype requires cell culture; PCR may be faster but limited scope)
Clinical Actionability	Immediate stratification for high-risk ALL/AML protocols; essential for DOT1L/Menin inhibitor trials	May require confirmatory FISH for unambiguous result; cannot resolve all complex translocations

Physician Insight & Safety Protocols

Mr. Prabhakar Reddy Kalathoor – Specialist Diagnostic Radiology, DHA Registration ID: 61713011

“As a diagnostic radiologist licensed by the Dubai Health Authority, I emphasize that the MLL rearrangement is a powerful prognostic marker, yet it must never be interpreted in isolation. The FISH result should be integrated with full morphological assessment, immunophenotyping, and NGS-based mutation panels. A positive finding demands immediate multidisciplinary tumor board discussion, while a negative result does not exclude other high-risk genetic lesions. Under UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, all patient data are securely handled and protected.”

⚠️ Medication Advisory

Do not discontinue any prescribed chemotherapy, steroids, or supportive medication without explicit instructions from your treating oncologist. Genetic test results are not a substitute for clinical evaluation or ongoing hematologic monitoring.

Patient Safety: Exclusion Criteria & Emergency Red Flags

Sample collection exclusion: Active, uncontrolled coagulopathy (INR >2.0, platelets <20×10⁹/L) unless cleared by the attending hematologist. Bone marrow aspiration must be performed in a hospital setting with resuscitation equipment available.
Prescription mandate: This test requires a valid DHA-licensed physician’s prescription with explicit clinical indication. It is not performed for elective surgery clearance, routine pregnancy, or travel certificates. Minors must have informed consent per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability.
Emergency escalation: If you experience new onset of fever >38.3°C, uncontrolled bleeding, confusion, or severe bone pain during the waiting period, proceed immediately to the nearest emergency department or call 998. Share your pending MLL result reference number with the triage team.
Post-test clinical correlation: A positive MLL rearrangement is associated with aggressive disease biology. Urgent scheduling with your oncology team is critical—do not delay consultation beyond 48 hours post-result notification.

Patient FAQ & Clinical Guidance

1. What exactly does the MLL (KMT2A) FISH detect and why is it needed for my leukemia subtype?

Answer: This FISH assay directly visualizes breaks within the KMT2A gene at 11q23, confirming the presence of high-risk translocations that drive aggressive AML or ALL. Even small percentages of interphase nuclei with aberrant signals are identified with >99% sensitivity, enabling your oncologist to select targeted agents like menin inhibitors or to prioritize early allogeneic stem cell transplant before chemoresistance develops.

2. Why must sample collection be performed in a hospital and not at home?

Answer: This test requires either a bone marrow aspirate (an invasive procedure with risk of bleeding or infection) or a peripheral blood draw. Bone marrow aspiration must be performed under sterile conditions in a hospital by a trained hematologist. Peripheral blood draw, while less invasive, is still restricted to hospital settings per DHA guidelines to ensure immediate medical support if complications arise. Mobile home phlebotomy is disabled for this test to guarantee patient safety and sample integrity.

3. Can I use my insurance to cover the 700 AED cost and how quickly will I receive the report?

Answer: Most UAE-based health insurance policies cover medically indicated MLL testing when accompanied by an oncologist’s prescription and an approved pre-authorization code. Our customer support team will verify your coverage instantly via WhatsApp at +971 54 548 8731—just share your Emirates ID front and back, policy card, and the doctor’s order. The final signed report, compliant with DHA electronic medical record standards, is released securely within 3–4 business days, with direct upload to your hospital portal if authorized.

UAE Regulatory & Data Privacy Adherence

Trust & Compliance Framework

DNA Labs UAE operates under DHA Facility License No. 1143 and complies with all UAE federal health data protection laws. Your personal health information is safeguarded in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and used solely for the purpose of diagnostic reporting. We do not share your data with third parties without your explicit consent. Our laboratory follows the ethical principles enshrined in Federal Decree-Law No. 4 of 2016 on Medical Liability for patient safety and informed consent.

Clinical & Logistical Metadata

Test Name	MLL (KMT2A) Gene Rearrangement by FISH – AML/ALL Panel
Price (AED)	700
Turnaround Time	3–4 working days
Sample Type / Matrix	Bone marrow aspirate or peripheral blood (hospital extraction only)
Methodology Used	Dual-color break-apart fluorescence in-situ hybridization (FISH)
ICD-10-CM Code	C92.00 (Acute myeloblastic leukemia, not having achieved remission)
LOINC Code	33679-2 (MLL gene rearrangement FISH)
DHA Facility License & Address	DHA License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE (DNA Labs UAE)